Julie Zhen Qin Wu

Array ( [id] => 16244876 [patent_doc_number] => 10744204 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-08-18 [patent_title] => Conjugated compounds comprising cysteine-engineered antibodies [patent_app_type] => utility [patent_app_number] => 15/302036 [patent_app_country] => US [patent_app_date] => 2015-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 37 [patent_no_of_words] => 35044 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15302036 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10325763 [patent_doc_number] => 20150210767 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-30 [patent_title] => 'STABLE ANTI-TNFR1 POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS & ANTAGONISTS' [patent_app_type] => utility [patent_app_number] => 14/682176 [patent_app_country] => US [patent_app_date] => 2015-04-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29386 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14682176 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10457978 [patent_doc_number] => 20150342993 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-12-03 [patent_title] => 'COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY' [patent_app_type] => utility [patent_app_number] => 14/676255 [patent_app_country] => US [patent_app_date] => 2015-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 18775 [patent_no_of_claims] => 53 [patent_no_of_ind_claims] => 43 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14676255 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10422618 [patent_doc_number] => 20150307629 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-10-29 [patent_title] => 'Bispecific antibodies that bind to CD38 and CD3' [patent_app_type] => utility [patent_app_number] => 14/673695 [patent_app_country] => US [patent_app_date] => 2015-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 161 [patent_figures_cnt] => 161 [patent_no_of_words] => 33420 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14673695 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10414325 [patent_doc_number] => 20150299335 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-10-22 [patent_title] => 'BI-SPECIFIC ANTIGEN-BINDING POLYPEPTIDES' [patent_app_type] => utility [patent_app_number] => 14/664018 [patent_app_country] => US [patent_app_date] => 2015-03-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 16044 [patent_no_of_claims] => 44 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14664018 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12165316 [patent_doc_number] => 09884075 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-02-06 [patent_title] => 'Domain-swap T cell receptors' [patent_app_type] => utility [patent_app_number] => 14/597908 [patent_app_country] => US [patent_app_date] => 2015-01-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 15458 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 171 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14597908 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15751331 [patent_doc_number] => 10617748 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-04-14 [patent_title] => Immunogenic control of tumours and tumour cells [patent_app_type] => utility [patent_app_number] => 14/589134 [patent_app_country] => US [patent_app_date] => 2015-01-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12711 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 159 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14589134 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11092372 [patent_doc_number] => 20160289341 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-06 [patent_title] => 'FABS-IN-TANDEM IMMUNOGLOBULIN AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 14/732088 [patent_app_country] => US [patent_app_date] => 2014-12-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 32281 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14732088 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10459568 [patent_doc_number] => 20150344584 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-12-03 [patent_title] => 'Modified Antigen Binding Molecules With Altered Cell Signaling Activity' [patent_app_type] => utility [patent_app_number] => 14/577180 [patent_app_country] => US [patent_app_date] => 2014-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 40911 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14577180 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10435847 [patent_doc_number] => 20150320859 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-11-12 [patent_title] => 'METHODS OF TREATING CANCER USING PD-L1 AXIS BINDING ANTAGONISTS AND VEGF ANTAGONISTS' [patent_app_type] => utility [patent_app_number] => 14/556774 [patent_app_country] => US [patent_app_date] => 2014-12-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 20683 [patent_no_of_claims] => 40 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14556774 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14551265 [patent_doc_number] => 10344075 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-07-09 [patent_title] => Engineered high-affinity human t cell receptors [patent_app_type] => utility [patent_app_number] => 15/037485 [patent_app_country] => US [patent_app_date] => 2014-11-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 12 [patent_no_of_words] => 23100 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15037485 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10437140 [patent_doc_number] => 20150322153 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-11-12 [patent_title] => 'ANTI-PD-L1 ANTIBODIES AND ARTICLES OF MANUFACTURE' [patent_app_type] => utility [patent_app_number] => 14/538072 [patent_app_country] => US [patent_app_date] => 2014-11-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 66037 [patent_no_of_claims] => 129 [patent_no_of_ind_claims] => 23 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14538072 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11083831 [patent_doc_number] => 20160280796 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-29 [patent_title] => 'ANTI-WT1/HLA BI-SPECIFIC ANTIBODY' [patent_app_type] => utility [patent_app_number] => 15/034782 [patent_app_country] => US [patent_app_date] => 2014-11-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 37 [patent_no_of_words] => 23608 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15034782 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10240452 [patent_doc_number] => 20150125447 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-05-07 [patent_title] => 'PHARMACEUTICAL COMBINATIONS COMPRISING CD33 ANTIBODIES AND DE-METHYLATING AGENTS' [patent_app_type] => utility [patent_app_number] => 14/533136 [patent_app_country] => US [patent_app_date] => 2014-11-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 11170 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14533136 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11053387 [patent_doc_number] => 20160250349 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-01 [patent_title] => 'A NOVEL STABLE FORMULATION' [patent_app_type] => utility [patent_app_number] => 15/030917 [patent_app_country] => US [patent_app_date] => 2014-10-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7700 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15030917 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11311724 [patent_doc_number] => 20160347834 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-01 [patent_title] => 'Anti-Podoplanin Antibody' [patent_app_type] => utility [patent_app_number] => 14/914704 [patent_app_country] => US [patent_app_date] => 2014-10-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 29796 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14914704 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10233259 [patent_doc_number] => 20150118253 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-04-30 [patent_title] => 'METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER AND INFECTIOUS DISEASE USING ALPHA(2) MACROGLOBULIN-ANTIGENIC MOLECULE COMPLEXES' [patent_app_type] => utility [patent_app_number] => 14/498419 [patent_app_country] => US [patent_app_date] => 2014-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 28398 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14498419 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11536930 [patent_doc_number] => 09611328 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-04-04 [patent_title] => 'Active protease-resistant antibody FC mutants' [patent_app_type] => utility [patent_app_number] => 14/492250 [patent_app_country] => US [patent_app_date] => 2014-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 30 [patent_no_of_words] => 18034 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 140 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14492250 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14596895 [patent_doc_number] => 10351631 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-07-16 [patent_title] => Constant chain modified bispecific, penta- and hexavalent Ig-M antibodies [patent_app_type] => utility [patent_app_number] => 14/916166 [patent_app_country] => US [patent_app_date] => 2014-09-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 30 [patent_no_of_words] => 16701 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 167 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14916166 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10692373 [patent_doc_number] => 20160038519 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-11 [patent_title] => 'ADMINISTRATION OF KARENITECIN FOR THE TREATMENT OF ADVANCED OVARIAN CANCER, INCLUDING CHEMOTHERAPY-RESISTANT AND/OR THE MUCINOUS ADENOCARCINOMA SUB-TYPES' [patent_app_type] => utility [patent_app_number] => 14/455847 [patent_app_country] => US [patent_app_date] => 2014-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 33093 [patent_no_of_claims] => 44 [patent_no_of_ind_claims] => 31 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14455847 [rel_patent_id] =>[rel_patent_doc_number] =>)